Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology Inc (CRDF) is a clinical-stage biotech company advancing novel therapies targeting cancers with high unmet need through its focus on PLK1 inhibition. This page provides investors and researchers with timely updates on clinical developments, strategic initiatives, and scientific breakthroughs driving the company's precision oncology pipeline.
Access the latest CRDF news including trial updates for RAS-mutated mCRC and other challenging cancers, partnership announcements, and regulatory milestones. Our curated collection features press releases on onvansertib developments, peer-reviewed data highlights, and management commentary to inform your analysis of this innovative oncology player.
Key content categories include Phase 2 trial progress updates, scientific conference presentations, and operational developments shaping Cardiff's therapeutic pipeline. Bookmark this page for streamlined tracking of CRDF's efforts to transform cancer treatment through mechanism-driven approaches.
Cardiff Oncology (Nasdaq: CRDF) has appointed Tod Smeal, Ph.D., as chief scientific officer and Charles Monahan, RPh, as senior vice president of regulatory affairs, as it advances its treatment pipeline. Smeal brings over 20 years of experience in targeted therapies, crucial for the development of onvansertib, a first-in-class Polo-like Kinase 1 inhibitor aimed at difficult-to-treat cancers. Monahan's regulatory expertise will facilitate the drug's journey towards approval. The company is focused on unmet needs in KRAS-mutated colorectal cancer and other severe cancers, aiming for improved patient outcomes.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced a conference call and webcast on January 18, 2022, at 5:00 PM ET, to discuss updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer. The data will also be featured at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), happening from January 20-22, 2022 in San Francisco. Cardiff is developing onvansertib, a first-in-class Polo-like Kinase 1 inhibitor, to improve cancer treatment outcomes in various indications.
Cardiff Oncology (Nasdaq: CRDF) announced its participation at the H.C. Wainwright BioConnect Virtual Conference from January 10 to 13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Cardiff Oncology focuses on developing precision medicine for cancer patients, specifically targeting KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Their investigational drug, onvansertib, is a third-generation Polo-like Kinase 1 inhibitor designed to improve treatment responses and overall survival.
Cardiff Oncology, a clinical-stage oncology company, announced updated data on its KRAS-mutated metastatic colorectal cancer program will be presented at the ASCO-GI from January 20-22, 2022, in San Francisco. The poster presentation titled "A phase 1b/2 trial of the PLK1 inhibitor onvansertib..." will showcase findings related to onvansertib in combination with FOLFIRI-bev for treating KRAS-mutated metastatic colorectal cancer. The abstract will be published on January 18, 2022, and is part of Poster Session C on January 22, 2022.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the grant of non-qualified stock options for 200,112 shares to two new employees on December 2, 2021. The options, set at an exercise price of $5.46 per share, will vest over four years, with 25% vesting after one year. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent in the oncology-focused firm. Cardiff is developing precision medicine for high-need cancer indications, including KRAS-mutated colorectal cancer and pancreatic cancer.
Cardiff Oncology (Nasdaq: CRDF) announced a $15 million equity investment from Pfizer (NYSE: PFE) to support its clinical programs for KRAS-mutated cancers, including colorectal and pancreatic cancer. Pfizer acquired 2.4 million shares at $6.22 each as part of its Breakthrough Growth Initiative. This collaboration aims to enhance Cardiff's efforts in developing onvansertib, a PLK1 inhibitor, alongside leveraging data from their clinical trials. Pfizer's VP, Adam Schayowitz, is set to join Cardiff's Scientific Advisory Board to further assist in innovative cancer therapies.
Cardiff Oncology (Nasdaq: CRDF) announced participation in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference from November 16 to December 2, 2021. Key presentations will focus on their precision medicine treatments for cancer, particularly targeting unmet needs in KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. These presentations will be available on-demand, with specific availability dates outlined for each conference.
Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its Phase 1b/2 trial for KRAS-mutated colorectal cancer, showing a 37% objective response rate (ORR) with onvansertib combined with standard treatment. The median progression-free survival (mPFS) reached 9.4 months, surpassing historical controls. The company strengthened its leadership team with new appointments and ended Q3 2021 with approximately $134 million in cash, despite increased operating expenses of $7.1 million, mainly due to clinical development efforts.
Cardiff Oncology (CRDF) reported promising results from its Phase 1b/2 trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). Of the 19 patients treated at the recommended dose, 42% achieved a partial response, significantly exceeding the historical 5-13% response rates. The median progression-free survival (mPFS) was 9.4 months, higher than the typical 4.5-5.7 months. The drug was well tolerated, with manageable adverse events. Further updates are expected as the trial progresses.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology firm, announced its participation in two upcoming virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021. During these events, CEO Mark Erlander and CFO James Levine will engage in presentations and one-on-one meetings. Cardiff is focused on developing onvansertib, a novel cancer treatment targeting unmet medical needs, particularly in KRAS-mutated cancers.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
